Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brain and Cervical Spinal Cord MRI Correlates of Motor Impairment and Vibratory Sensation in Patients with Multiple Sclerosis
Multiple Sclerosis
S42 - Multiple Sclerosis: Biomarkers/Neuroimaging (1:12 PM-1:24 PM)
002
cSC focal lesions and volume loss represent pathological processes that strongly contribute to clinical disability in MS. However, how different MS-related cSC abnormalities may be associated with specific motor and sensory dysfunctions still needs to be fully explored. 
To identify MRI features of cervical spinal cord (cSC) damage able to predict a more severe clinical disability and impairment in motor and sensory functions in multiple sclerosis (MS) patients.

One hundred fifty-one MS patients and 69 age- and sex-matched healthy controls (HC) underwent brain and cSC 3T MRI acquisition and a comprehensive clinical assessment including evaluation of Expanded Disability Status Scale (EDSS), 9-hole peg test (9-HPT), finger tapping test (FTT), timed 25-foot walk test (T25FWT) and vibration detection threshold (VDT). Using random forest analyses, we investigated whether brain and cSC MRI measures (T2-hyperintense lesion volume [T2-LV] and total, gray matter [GM] and white matter [WM] cross-sectional areas [CSA] at C2-C3 level) were informative predictors of EDSS disability milestones (EDSS≥3.0, 4.0 and 6.0), impairment at pyramidal and sensory functional systems (P-FS and S-FS ≥2), as well as at 9-HPT, FTT and T25FWT (z-scores≤5th percentile of HC), and higher VDT.

Different combinations of brain and cSC MRI measures were informative predictors of EDSS milestones (out-of-bag [OOB]-area under the curve [AUC]=0.879-0.900), VDT (OOB-R2=0.194), and impairment at P-FS (OOB-AUC=0.820), S-FS (OOB-AUC=0.795), 9-HPT (OOB-AUC=0.793), FTT (OOB-AUC=0.740), T25FWT (OOB-AUC=0.825). For all these clinical outcomes, cSC GM CSA was identified as the most relevant predictor, except for 9-HPT, for which cSC T2-LV was the best predictor.

A multiparametric approach including brain and cSC MRI measures may explain a more severe clinical disability in MS with high accuracy. cSC GM atrophy represents an impactful pathological substrate specifically contributing to motor and sensory impairment in MS.

Authors/Disclosures
Tetsu Morozumi, PT (IRCCS Ospedale San Raffaele)
PRESENTER
Mr. Morozumi has nothing to disclose.
Paolo Preziosa (Ospedale San Raffaele) Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Alessandro Meani No disclosure on file
Giorgia Pessina No disclosure on file
Matteo Azzimonti No disclosure on file
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.